Invention Grant
- Patent Title: Treatment of glaucoma
-
Application No.: US16614279Application Date: 2018-05-16
-
Publication No.: US11291684B2Publication Date: 2022-04-05
- Inventor: Lars Bruce , Adam Bruce
- Applicant: TX MEDIC AB
- Applicant Address: SE Viken
- Assignee: TX MEDIC AB
- Current Assignee: TX MEDIC AB
- Current Assignee Address: SE Viken
- Agency: Porter Wright Morris & Arthur LLP
- Priority: SE1750615-5 20170517
- International Application: PCT/SE2018/050506 WO 20180516
- International Announcement: WO2018/212708 WO 20181122
- Main IPC: A61K31/721
- IPC: A61K31/721 ; A61P27/06 ; A61K31/737 ; A61K9/00

Abstract:
The present embodiments generally relate to dextran sulfate, or a pharmaceutically acceptable salt thereof, for use in treating, inhibiting or preventing glaucoma in a subject. Dextran sulfate of the embodiments achieves a reduction and normalization of intraocular pressure, a neuroprotective effect in terms of preserving retinal ganglion cells and retinal nerve fiber layer and dissolves established trabecular meshwork scar elements.
Public/Granted literature
- US20210315920A1 TREATMENT OF GLAUCOMA Public/Granted day:2021-10-14
Information query